



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tacedinaline

Cat. No.:	HY-50934
CAS No.:	112522-64-2
Molecular Formula:	C ₁₅ H ₁₅ N ₃ O ₂
Molecular Weight:	269.3
Target:	HDAC; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 50 mg/mL (185.67 mM)					
	* "≥" means soluble, but saturation unknown.					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	3.7133 mL	18.5667 mL	37.1333 mL	
		5 mM	0.7427 mL	3.7133 mL	7.4267 mL	
10 mM	0.3713 mL	1.8567 mL	3.7133 mL			
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline					
	Solubility: ≥ 2.5 mg/mL (9.28 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC ₅₀ s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.		
IC ₅₀ & Target	HD1 0.9 μM (IC ₅₀)	HD2 0.9 μM (IC ₅₀)	HD3 1.2 μM (IC ₅₀)
In Vitro	Tacedinaline (N-acetyldinaline) is a novel oral compound with a wide spectrum of antitumor activity in preclinical models. The mechanism of action may involve inhibition of histone deacetylation and cell cycle arrest. Tacedinaline (N-acetyldinaline) is combined with antineoplastic agents commonly used in non-small cell lung cancer cell line management, a marked synergism of action (R=1.8, R=1.5) is observed between Tacedinaline (N-acetyldinaline) (40 μM) and gemcitabine (0.01 μM) at 48 and 72 h of treatment ^[2] .		

Tacedinaline (N-acetyldinaline) inhibits mitogen-stimulated blood lymphocyte proliferation with an IC₅₀ value of 3 μM^[4].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tacedinaline (CI-994) can effect lymphoid tissue in rats within 1 day of a single oral dose, that effects are generally reversible within 7 days^[4].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[4]

Rats: To characterize the effects of Tacedinaline (CI-994) on lymphoid tissue, male rats are administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue^[4].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2023 Sep 22;14(1):5916.
- Nutrients. 2023 Jun 15, 15(12), 2760.
- Int J Mol Sci. 2022 Apr 2;23(7):3980.
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
- Front Neurosci. 2021 Oct 6;15:674745.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6.
- [2]. Loprevite M, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48.
- [3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56.
- [4]. Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA